Maxidex

Dexamethasone, the active ingredient in Maxidex, is a corticosteroid presented as an ophthalmic solution for ocular use. It treats inflammatory eye conditions such as post‑operative inflammation, uveitis, and allergic conjunctivitis in patients requiring anti‑inflammatory therapy.

GNH USA supplies Maxidex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxidex is a corticosteroid eye drop used to manage inflammatory conditions of the eye.

- Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery. - Anterior uveitis: controls intra‑ocular inflammation and prevents tissue damage. - Allergic conjunctivitis: alleviates inflammatory response and improves comfort.

Adverse reactions may occur with ocular dexamethasone use.

Common Side Effects: - Transient eye irritation or burning sensation. - Increased intraocular pressure. - Blurred vision. - Temporary tearing. - Mild conjunctival hyperemia.

Serious or Rare Side Effects: - Secondary ocular infection (bacterial or fungal). - Cataract formation with prolonged use. - Glaucoma or sustained intraocular pressure rise. - Delayed wound healing after surgery. - Severe allergic reaction (e.g., angioedema).

Careful assessment and monitoring are required when using Maxidex.

- Pregnancy: consult a physician; limited safety data are available. - Breastfeeding: caution; dexamethasone may be excreted in milk. - Pre‑existing glaucoma: monitor intraocular pressure closely. - Concurrent systemic steroid therapy: risk of additive systemic effects. - Contact lens wear: discontinue lenses during treatment. - Store at room temperature: keep in original container, protect from light and moisture.

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic steroid exposure and side‑effects. - Anticholinergic eye drops: can diminish anti‑inflammatory efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: possible additive intraocular pressure increase. - NSAID eye drops: overlapping anti‑inflammatory actions may require dose adjustment. - Antiviral eye medications: potential reduction in antiviral activity.